CAESAREA, Israel, October 6 /PRNewswire/ --
- Remon Medical Presents the First European use of its Implantable Hemodynamic Monitor for Home use. The Remon ImPressure(TM) Offers on-Demand, Non-Invasive Self-Monitoring of Pulmonary Artery Pressures by the Patient
Remon Medical Technologies, Inc., a privately held medical device company, today announced the first European use of its implantable hemodynamic monitor. The Remon(TM) ImPressure(TM)offers on-demand, non-invasive, leadless self-monitoring of pulmonary artery pressure by the patient at home. ImPressure(TM) devices were implanted in four patients, at two sites in Germany. In all four cases, pulmonary artery pressure readings were successfully transmitted to the hand-held home monitor and the clinic unit immediately after the implantation and in subsequent follow-ups.
Professor Dr. Uta Hoppe, of the Internal Medicine Department, University of Cologne noted that "After implanting the Remon ImPressure, the hand-held home unit provides the patient with a unique tool for self monitoring. This monitor will be easy for my patients to use at home, and is expected to give early warning of the need for treatment, avoiding hospitalization and deterioration in the patient's condition."
Data from the hand-held monitor can be downloaded to a laptop clinic system, displaying a history of the patient's pulmonary pressure readings. "This graphic display of pulmonary artery pressure waveform will certainly assist in determining optimal treatment for each patient, resulting in better disease management," added Professor Hoppe.
The Remon ImPressure is introduced percutaneously, via a simple vein catheterization procedure, using jugular or femoral access. The miniature device, based on Remon's proprietary acoustic technology, is wireless and leadless. The patient uses a portable battery operated hand-held unit to interrogate the implant. The measurement can be taken at home, or away from home, without any special preparation, and without exposing the patient to radiation.
Professor Dr. Horst Sievert, Director of the CardioVascular Center Frankfurt, Sankt Katharinien, commented: "I was impressed by the simplicity and ease of delivering the ImPressure to the pulmonary artery. The physician's ability to choose between intra-jugular and femoral approaches and the low profile of the delivery system add significantly to the system flexibility."
Hezi Himelfarb, Remon's CEO, said: "We are excited to see our device implanted for the first time in Europe, as part of a trial to meet the requirements for CE mark regulatory approval. Our device demonstrates the inherent value of Remon's unique acoustic communication. We believe that our technology has many other applications that will dramatically impact several areas within medicine".
About Remon Medical
Remon Medical Technologies, Inc. develops and commercializes smart, miniature implants which enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. Remon's enabling technology utilizes wireless communication to exchange energy and data with and between miniature devices placed deep inside the body, in order to monitor a variety of physiological parameters and create therapeutic responses. The company's RemonIBC(TM) - Intra-Body Communication technology allows wireless wakeup of totally dormant implantable devices and communication between several devices implanted inside the body in a totally wireless fashion.
Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release.
Remon is backed by leading global investors, including Concord Ventures, Polaris Venture Partners, Lilly Ventures, KBL Healthcare Ventures, Ofer Hi-Tech Group, Triathlon Medical Ventures, Medica Venture Partners and Guidant Corporation.
For more information about Remon Medical, visit www.RemonMedical.com
Remon Medical Technologies Inc.
U.S. Mobile: +1-(201)-658-6383
OUS Mobile: +972-52-249-7044
Remon Medical Technologies inc